Insider trade

CEO exercised or converted 234K ROIV derivative securities

Traded Dec 15, 2025 · Filed Dec 18, 2025

Roivant SciencesROIV

234K
Shares · @ $4.06

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 15, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 18, 2025

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001140361-25-045906

Filed / recorded

Dec 18, 2025, 7:00 AM UTC

Added to OQRO

Oct 6, 2026, 8:46 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Roivant Sciences Ltd.

Issuer CIK

1635088

Ticker

ROIV

Reporting person

Matthew Gline

Relationship

Director, Officer

Officer title

CEO

Security

Common Shares

Table

Non-derivative (Table I)

Transaction date

Dec 15, 2025

Transaction code

M

Shares / units

234,096

Price per share

$4.06

Acquired / disposed

Acquired (A)

Shares owned after

17,521,177

Ownership form

Direct

Amendment

No

Around the same time

200KShares · @ $3.85

9mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record

CEO sold ~$4.38M of Roivant Sciences

Automatic sale9mo ago

200KDerivative units

9mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record